BioVaxys Announces Share Consolidation to Strengthen Market Position
Vancouver, BC – September 5, 2025 – BioVaxys Technology Corp. (OTC: BVXV), a biopharmaceutical company dedicated to advancing novel vaccine and antibody therapies, today announced a significant corporate action: a share consolidation. The company plans to implement a 1-for-50 reverse stock split, a strategic move aimed at enhancing its market standing and preparing for future growth opportunities.
This consolidation, effective for trading purposes on September 8, 2025, will reduce the number of outstanding common shares of the company. Specifically, every 50 existing common shares will be consolidated into one new common share. This adjustment is expected to increase the per-share market price of BioVaxys’ stock, a common objective for companies looking to meet exchange listing requirements and improve investor appeal.
The decision to proceed with a share consolidation is a proactive step by BioVaxys’ leadership. By increasing the per-share price, the company anticipates it will become a more attractive investment for a broader range of institutional and retail investors. This can be particularly beneficial for companies aiming to secure future funding rounds or to achieve and maintain compliance with minimum bid price requirements of major stock exchanges.
BioVaxys has been actively engaged in developing innovative solutions within the biopharmaceutical sector, focusing on areas with significant unmet medical needs. The company’s pipeline includes promising vaccine candidates and antibody-based therapies. This share consolidation is intended to provide a more robust financial and market foundation as BioVaxys continues its research and development efforts and pursues strategic partnerships.
Shareholders are advised that the consolidation will be effected automatically, and fractional shares resulting from the consolidation will be handled according to the company’s previously filed corporate documents and applicable regulations. Shareholders should consult their individual brokerage accounts or contact their financial advisors for specific details regarding how the consolidation will affect their holdings.
BioVaxys Technology Corp. remains committed to its mission of developing life-saving and life-enhancing therapies. The company expresses gratitude for the continued support of its shareholders as it navigates this strategic transition, aiming to unlock greater value and advance its promising scientific endeavors.
BIOVAXYS ANNOUNCES SHARE CONSOLIDATION
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘BIOVAXYS ANNOUNCES SHARE CONSOLIDATION’ at 2025-09-05 21:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.